From Wikipedia the free encyclopedia
|Micrograph showing ground glass hepatocytes, which are seen in chronic hepatitis B infections (a type of viral hepatitis), and represent accumulations of viral antigen in the endoplasmic reticulum. H&E stain.|
|Specialty||Infectious diseases, gastroenterology|
The most common causes of viral hepatitis are the five unrelated hepatotropic viruses hepatitis A, B, C, D, and E. Other viruses can also cause liver inflammation, including cytomegalovirus, Epstein–Barr virus, and yellow fever. There also have been scores of recorded cases of viral hepatitis caused by herpes simplex virus.
Mode Of Transmission
Viral hepatitis is either transmitted through contaminated food or water (A, E) or via blood and body fluids (B, C). The viruses transmitted through water and food are mostly self-limited, resulting in acute illness with full resolution. The blood borne viruses (B, C) can cause both acute and chronic liver disease and can be transmitted from mother to child during birth, through contact with body fluids during sex, unsafe injections and through unscreened blood transfusions.
|Hepatitis A virus (HAV)||Hepatitis B virus (HBV)||Hepatitis C virus (HCV)||Hepatitis D virus (HDV)||Hepatitis E virus (HEV)|
|Viral species||Hepatovirus A||Hepatitis B virus||Hepacivirus C||Hepatitis delta virus||Orthohepevirus A|
|Viral family||Picornaviridae||Hepadnaviridae||Flaviviridae||Incertae sedis||Hepeviridae|
|Antigens||HBsAg, HBeAg||Core antigen||Delta antigen|
|Incubation period||20–40 days||45–160 days||15–150 days||30–60 days||15–60 days|
|Severity/Chronicity||Mild; acute||Occasionally severe; 5–10% chronic||Subclinical; 70% chronic||Exacerbates symptoms of HBV; chronic with HBV||Mild in normal patients; severe in pregnant women; acute|
|Vaccine||2 injections; at least 20 years of protection||3 injections; lifetime protection||None available||None available, but not considered necessary; Hep B vaccine provides protection||Investigational (approved in China)|
Viral hepatitis types
Hepatitis A or infectious jaundice is caused by hepatitis A virus (HAV), a picornavirus transmitted by the fecal-oral route often associated with ingestion of contaminated food. It causes an acute form of hepatitis and does not have a chronic stage. A patient's immune system makes antibodies against HAV that confer immunity against future infection. People with hepatitis A are advised to rest, stay hydrated and avoid alcohol. A vaccine is available that will prevent HAV infection for up to 10 years. Hepatitis A can be spread through personal contact, consumption of raw sea food, or drinking contaminated water. This occurs primarily in third world countries. Strict personal hygiene and the avoidance of raw and unpeeled foods can help prevent an infection. Infected people excrete HAV with their feces two weeks before and one week after the appearance of jaundice. The time between the infection and the start of the illness averages 28 days. (ranging from 15 to 50 days), Most patients recover fully within 2 months, although approximately 15% of affected people may experience continuous or relapsing symptoms from six months to a year following initial diagnosis.
|Faecal HAV||2–4 weeks or 28 days||–||Early detection|
|Ig M anti HAV||4–12 weeks||Enzyme immunoassay for antibodies||During acute Illness|
|Ig G anti HAV||5 weeks–persistent||Enzyme immunoassay for antibodies||Old infection or reinfection|
Hepatitis B is caused by the hepatitis B virus, a hepadnavirus that can cause both acute and chronic hepatitis. Chronic hepatitis develops in the 15% of adults who are unable to eliminate the virus after an initial infection. Identified methods of transmission include contact with blood, blood transfusion (now rare), unsanitary tattoos, sex (through sexual intercourse or contact with bodily fluids), or mother-to-child by breast feeding; there is minimal evidence of transplacental crossing. However, in about half of cases the source of infection cannot be determined. Blood contact can occur by sharing syringes in intravenous drug use, shaving accessories such as razor blades, or touching wounds on infected persons. Needle-exchange programmes have been created in many countries as a form of prevention.
Patients with chronic hepatitis B have antibodies against the virus, but not enough to clear the infected liver cells. The continued production of virus and countervailing antibodies is a likely cause of the immune complex disease seen in these patients. A vaccine is available to prevent infection for life. Hepatitis B infections result in 500,000 to 1,200,000 deaths per year worldwide due to the complications of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Hepatitis B is endemic in a number of (mainly South-East Asian) countries, making cirrhosis and hepatocellular carcinoma big killers. There are eight treatment options approved by the U.S. Food and Drug Administration (FDA) available for persons with a chronic hepatitis B infection: alpha-interferon, pegylated interferon, adefovir, entecavir, telbivudine, lamivudine, tenofovir disoproxil and tenofovir alafenamide with a 65% rate of sustained response.
Hepatitis C (originally "non-A non-B hepatitis") is caused by hepatitis C virus (HCV), an RNA virus of the family Flaviviridae. HCV can be transmitted through contact with blood (including through sexual contact if the two parties' blood is mixed) and can also cross the placenta. Hepatitis C usually leads to chronic hepatitis, culminating in cirrhosis in some people. It usually remains asymptomatic for decades. Patients with hepatitis C are susceptible to severe hepatitis if they contract either hepatitis A or B, so all persons with hepatitis C should be immunized against hepatitis A and hepatitis B if they are not already immune, and avoid alcohol. HCV can lead to the development of hepatocellular carcinoma, however, only a minority of HCV-infected individuals develop cancer (1–4% annually), suggesting a complex interplay between viral gene expression and host and environmental factors to promote carcinogenesis. The risk is increased two-fold with active HBV coinfection and a 21% increase in mortality compared to those with latent HBV and HCV. HCV viral levels can be reduced to undetectable levels by a combination of interferon and the antiviral drug ribavirin. The genotype of the virus is the primary determinant of the rate of response to this treatment regimen, with genotype 1 being the most resistant.
Hepatitis C is the most common chronic blood-borne infection in the United States.
|HCV-RNA||1–3 weeks or 21 days||PCR||Demonstrates presence or absence of virus||Results may be intermittent during course of infection. Negative result is not indicative of absence.|
|anti-HCV||5–6 weeks||Enzyme Immunoassay for antibodies||Demonstrates past or present infection||High false positive in those with autoimmune disorders and populations with low virus prevalence.|
|ALT||5–6 weeks||–||Peak in ALT coincides with peak in anti-HCV||Fluctuating ALT levels is an indication of active liver disease.|
Hepatitis D is caused by the hepatitis D virus (HDV), or hepatitis delta virus; it belongs to the genus Deltavirus. HDV is similar to a satellite virus as it can only propagate in the presence of the hepatitis B virus, depending on the helper function of HBV for its replication and expression. It has no independent life cycle, but can survive and replicate as long as HBV infection persists in the host body. It can only cause infection when encapsulated by hepatitis B virus surface antigens. The vaccine for hepatitis B protects against hepatitis D virus because of the latter's dependence on the presence of hepatitis B virus for it to replicate.
Hepatitis E is caused by the Hepatitis E virus (HEV), from the family Hepeviridae. It produces symptoms similar to hepatitis A, although it can take a fulminant course in some patients, particularly pregnant women (mortality rate about 20%); chronic infections may occur in immune-compromised patients. It is more prevalent in the Indian subcontinent. The virus is feco-orally transmitted and is usually self-limited.
Hepatitis F virus
Hepatitis F virus (HFV) is a hypothetical virus linked to certain cases of hepatitis. Several hepatitis F virus candidates emerged in the 1990s, but none of these reports have been substantiated.
GB virus C
The GB virus C is a virus that is probably spread by blood and sexual contact. It was initially identified as Hepatitis G virus. There is very little evidence that this virus causes hepatitis, as it does not appear to replicate primarily in the liver. It is now classified as GB virus C.
2022 hepatitis of unknown origin
In 2022, several hundred cases of acute hepatitis of probable infectious origin were reported worldwide. As of May 2022, the virus causing these cases has not been identified, but an adenovirus is suspected.
Relationship between hepatitis C virus and liver cancer
Hepatitis C virus (HCV) can cause acute and chronic infections that are a major cause of hepatocellular carcinoma (HCC), advanced hepatic fibrosis and cirrhosis.
HCC is a major cause of death in patients with chronic HCV infection. Regarding the pathogenesis of HCC associated with HCV, that virus may play direct or indirect roles.
A major risk for the development of HCC is persistent infection with HCV, and the highest risk for HCC development is associated with co-infection of HBV with HDV, HCV or HIV.
Risk factors that can lead to the development of HCC in those with chronic HCV include synchronous liver diseases, viral genotype, diabetes mellitus, and obesity. Lifestyle factors such as liver steatosis, smoking, and alcohol use can accelerate progression to HCC and liver decompensation in patients with HCV.
The purpose of HCV treatment is to eliminate the infection, reduce the transmission to other people and decrease the risk of HCC development.
- Arenaviruses: Guanarito virus, Junín virus, Lassa fever virus, Lujo virus, Machupo virus, and Sabiá virus
- Bunyaviruses: Crimean–Congo hemorrhagic fever virus, Dobrava virus, Hantaan virus, Puumala virus, Rift Valley fever virus, and Seoul virus
- Coronavirus: severe acute respiratory syndrome virus
- Erythrovirus: Parvovirus B19
- Filoviruses: Ebola virus and Marburg virus
- Flaviviruses: dengue, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and yellow fever virus
- Herpesviruses: cytomegalovirus, Epstein–Barr virus, varicella-zoster virus, human herpesvirus 6, human herpesvirus 7, and human herpesvirus 8
- Orthomyxoviruses: influenza
- Picornaviruses: echovirus
- Reovirus: Colorado tick fever virus, reovirus 3
Additionally, a casual role between the virus KIs-V and hepatitis is suspected based on a 2011 study that isolated KIs-V from four patients with raised serum alanine transferases without other known cause.
- "National Library of Medicine » Medical Subject Headings »Virus Diseases (C02) » Hepatitis, Viral, Human (C02.440) » Scope Note".
- "Hepatitis | MedlinePlus". Retrieved 2017-06-23.
- "Validate User". academic.oup.com.
- "Hepatitis B". World Health Organization. Retrieved 5 October 2021."Hepatitis C". World Health Organization. Retrieved 5 October 2021.
- Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. (September 2016). "The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013". Lancet. 388 (10049): 1081–1088. doi:10.1016/S0140-6736(16)30579-7. PMC 5100695. PMID 27394647.
- Kuo, Infectious Causes of Jaundice, ATSU School of Osteopathic Medicine Arizona, June 2012
- "Hepatitis a Q&As for Health Professionals | CDC". 9 April 2021.
- Tayor JM (2009). Desk Encyclopedia of Human and Medical Virology. Boston: Academic Press. p. 121. ISBN 978-0-12-375147-8.
- "CDC Hepatitis A FAQ". Retrieved 2008-03-03.
- "CDC Hepatitis A Fact Sheet". Retrieved 2008-03-03.
- "AccessMedicine – Internal Medicine Clinical Resource". accessmedicine.mhmedical.com.
- Ringehan, Marc; McKeating, Jane A.; Protzer, Ulrike (2017-10-19). "Viral hepatitis and liver cancer". Philosophical Transactions of the Royal Society B: Biological Sciences. 372 (1732): 20160274. doi:10.1098/rstb.2016.0274. ISSN 0962-8436. PMC 5597741. PMID 28893941.
- "CDC DVH—Hepatitis C Information For the Health Professional". Retrieved 2010-01-14.
- "WHO | Hepatitis C". Who.int. 2010-12-08. Retrieved 2012-08-26.
- "U.S. National Library of Medicine "Delta Agent (hepatitis D)"".
- Stark K, Bienzle U, Hess G, Engel AM, Hegenscheid B, Schluter V (1996). "Detection of the hepatitis G virus genome among injecting drug users, homosexual and bisexual men, and blood donors". J. Infect. Dis. 174 (6): 1320–3. doi:10.1093/infdis/174.6.1320. PMID 8940225.
- Linnen J, Wages J, Zhang-Keck ZY, et al. (1996). "Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent". Science. 271 (5248): 505–8. Bibcode:1996Sci...271..505L. doi:10.1126/science.271.5248.505. PMID 8560265. S2CID 12931655.
- Pessoa MG, Terrault NA, Detmer J, et al. (1998). "Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic". Hepatology. 27 (3): 877–80. doi:10.1002/hep.510270335. PMID 9500722.
- "00.026. Flaviviridae". ICTVdB Index of Viruses. Archived from the original on 2008-05-11. Retrieved 2008-08-09.
- "Joint ECDC-WHO Regional Office for Europe Hepatitis of Unknown Origin in Children Surveillance Bulletin". cdn.ecdc.europa.eu. Archived from the original on 14 May 2022. Retrieved 14 May 2022.
- "Multi-Country – Acute, severe hepatitis of unknown origin in children". www.who.int. Archived from the original on 24 April 2022. Retrieved 24 April 2022.
- Adenovirus probable cause of mysterious child hepatitis. BBC News, 25 April 2022. Retrieved 25 April 2022.
- de Oliveria Andrade LJ, D'Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R (January 2009). "Association between hepatitis C and hepatocellular carcinoma". Journal of Global Infectious Diseases. 1 (1): 33–7. doi:10.4103/0974-777X.52979. PMC 2840947. PMID 20300384.
- Ringelhan M, McKeating JA, Protzer U (October 2017). "Viral hepatitis and liver cancer". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 372 (1732). doi:10.1098/rstb.2016.0274. PMC 5597741. PMID 28893941.
- Persico M, Bruno S, Costantino A, Mazza M, Almasio PL. The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol. 2011;2011:314301. doi: 10.4061/2011/314301.
- Miguet JP, Coaquette A, Bresson-Hadni S, Lab M (1990). "[The other types of viral hepatitis]". Rev Prat (in French). 40 (18): 1656–9. PMID 2164704.
- Chau TN, Lee KC, Yao H, et al. (February 2004). "SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases". Hepatology. 39 (2): 302–10. doi:10.1002/hep.20111. PMC 7165792. PMID 14767982.
- Naides SJ (May 1998). "Rheumatic manifestations of parvovirus B19 infection". Rheum. Dis. Clin. North Am. 24 (2): 375–401. doi:10.1016/S0889-857X(05)70014-4. PMID 9606764.
- Xiong W (November 2010). "[Clinical efficacy of treating infant cytomegalovirus hepatitis with ganciclovir and impact on cytokines]". Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (in Chinese). 26 (11): 1130–2. PMID 21322282.
- Okano M, Gross TG (June 2012). "Acute or chronic life-threatening diseases associated with Epstein–Barr virus infection". The American Journal of the Medical Sciences. 343 (6): 483–9. doi:10.1097/MAJ.0b013e318236e02d. PMID 22104426. S2CID 38640928.
- Anderson DR, Schwartz J, Hunter NJ, Cottrill C, Bisaccia E, Klainer AS (September 1994). "Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature". Archives of Internal Medicine. 154 (18): 2101–6. doi:10.1001/archinte.1994.00420180111013. PMID 8092915.
- Gallegos-Orozco JF, Rakela-Brödner J (October 2010). "Hepatitis viruses: not always what it seems to be". Revista Médica de Chile. 138 (10): 1302–11. doi:10.4067/S0034-98872010001100016. PMID 21279280.
- Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I (September 2011). "Liver involvement during influenza infection: perspective on the 2009 influenza pandemic". Influenza and Other Respiratory Viruses. 6 (3): e2–5. doi:10.1111/j.1750-2659.2011.00287.x. PMC 4941665. PMID 21951624.
- Satoh K, Iwata-Takakura A, Osada N, et al. (October 2011). "Novel DNA sequence isolated from blood donors with high transaminase levels". Hepatology Research. 41 (10): 971–81. doi:10.1111/j.1872-034X.2011.00848.x. PMID 21718400. S2CID 22339362.